N/A N=1,390 Real-world Study of Dedifferentiated Liposarcoma Patients in China
Dedifferentiated Liposarcoma
Primary: Cohort 1: Overall Survival — 13.4; 11.9; 8.1 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=52 Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial
Advanced and / or Metastatic Liposarcoma
Primary: Progression-free Survival (PFS) Assessed 12 Weeks After Start of Treatment — 54.1; 46.2 percentage of participants
Phase 3 N=342 Selinexor in Advanced Liposarcoma
Dedifferentiated Liposarcoma
Primary: Phase 3 Double Blind: Progression-free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 — 2.83; 2.07 Months — p=0.0114
Phase 2 N=73 Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
Sarcoma, Soft Tissue · Soft Tissue Sarcoma · Undifferentiated Pleomorphic Sarcoma
Primary: Progression-free Survival (PFS) (Arm 1 Only) — 5.48 months
Phase 2 N=13 Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery
Liposarcoma
Primary: Confirmed Overall Response Rate Per the RECIST 1.1 Criteria — 0 percentage of patients
Phase 3 N=577 A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma
Advanced Liposarcoma or Leiomyosarcoma
Primary: Overall Survival (OS) — 13.73; 13.14 Months
Phase 3 N=400 Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma
Liposarcoma, Dedifferentiated
Primary: Progression-free Survival (PFS) — 8.18; 8.38; 7.16 Months — p=0.0956
N/A N=48 Assessment of Helical Tomotherapy Radiotherapy (54 Gy) Followed by Surgery in Retro-peritoneal Liposarcoma
Liposarcoma
Primary: Cumulative Incidence Rate of Local Recurrence and Competing Risks (All Patients) — 16.89; 10.42 percentage of participants
Phase 2 N=29 Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma
Liposarcoma,Myxoid
Primary: Percentage of Participants With Pathological Complete Response (pCR) — 13 percentage of participants
Phase 2 N=37 Sorafenib and Dacarbazine in Soft Tissue Sarcoma
Sarcoma · Synovial Sarcoma · Leiomyosarcoma
Primary: Overall Objective Response — 5; 22; 8 participants
Phase 2 N=23 Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma
Neoplasms
Primary: Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Investigator Assessment — 20; 40 Percentage of participants
Phase 2 N=80 Dacarbazine for Metastatic Soft Tissue and Bone Sarcoma
Sarcoma
Primary: Best Anatomical Tumor Response — 0; 2; 22; 30 participants
Phase 2 N=42 Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma
Liposarcoma · Surgically Unresectable Liposarcoma · Metastatic Liposarcoma
Primary: 12-week Progression Free Rate — 68.29 percentage of participants
Phase 2 N=90 PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma
Sarcoma · Liposarcoma
Primary: Progression Free Survival at 12 Weeks — 66; 57.2 percentage of particpants
Phase 2 N=48 Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma
Liposarcoma · Leiomyosarcoma · Fibrosarcoma
Primary: Number of Participants With Overall Response (OR) — 1 participants
Phase 2 N=57 A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas
Sarcoma · Liposarcoma · Leiomyosarcoma
Primary: 12-week Progression Free Survival (PFS) — 69.6; 36.8; 52.6 percentage of participants
Phase 2 N=25 Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma
Sarcoma
Primary: Number of Patients With Dose Limiting Toxicities. — 0; 1; 0 Participants
Phase 2 N=40 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma
Adult Alveolar Soft-part Sarcoma · Adult Angiosarcoma · Adult Epithelioid Sarcoma
Primary: Objective Tumor Response (Complete and Partial) — 2 Participants
Phase 2 N=20 Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma
Pleomorphic Rhabdomyosarcoma · Stage IIB Adult Soft Tissue Sarcoma AJCC v7 · Stage III Adult Soft Tissue Sarcoma AJCC v7
Primary: Pathologic Response Rate, Defined as the Percentage of Participants With Greater Than or Equal to 95% Necrosis. — 20 % of participants
Phase 3 N=588 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
Adult Alveolar Soft-part Sarcoma · Adult Angiosarcoma · Adult Epithelioid Sarcoma
Primary: Probability for Event Free Survival. — 0.8984; 0.7647; 0.6079; 0.4873 Probability of EFS at 5 years
N/A N=2,165 Patterns of Care and Outcomes in METAstatic Soft Tissue SARComa
Sarcoma · Metastases · Chemotherapy
Primary: Correlation Between Time to Next Treatment (TNT) and Overall Survival (OS) Under First-line Treatment — 0.76 correlation coefficient
Phase 2 N=147 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
Adult Angiosarcoma · Adult Epithelioid Sarcoma · Adult Leiomyosarcoma
Primary: Overall Response Rate Measured by Complete Response (CR) Rate and Partial Response (PR) Rate as Determined by RECIST — 1; 0; 0; 0 participants
N/A N=266 Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma
Sarcoma
Primary: Number of Patients With Abdominal Recurrence or Death — 72; 73; 61; 60 Participants — p=0.955
Phase 2 N=29 Sitravatinib in Advanced Liposarcoma and Other Soft Tissue Sarcomas
Liposarcoma · Metastatic Liposarcoma
Primary: Number of Participants Who Were Progression Free — 12 Participants
Phase 2 N=51 S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas
Sarcoma
Primary: Objective Response (Confirmed, Complete and Partial) — 1; 0; 1; 8 participants
Phase 2 N=97 ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer
Soft Tissue Sarcoma
Primary: Progression-free Survival (PFS) (Cohort 1 Only) — 5.0597 months
Phase 3 N=87 Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
Desmoid Fibromatosis
Primary: Progression-free Survival(PFS) Rate — 7; 22; 42; 13 Participants — p=<0.001
Phase 2 N=17 External Beam Radiation With Intratumoral Injection of Dendritic Cells As Neo-Adjuvant Treatment for Sarcoma
Soft Tissue Sarcoma
Primary: Overall Response Rate (ORR) — 9; 3; 6 participants
Phase 2 N=54 Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma
Sarcoma
Primary: Objective Response Rate — 6; 5; 14 participants
Phase 2 N=15 Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07)
Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor · Metastatic Osteosarcoma · Recurrent Adult Soft Tissue Sarcoma
Primary: Change in Fludeoxyglucose (FDG) Uptake (Maximal Standardized Uptake Value, or SUVmax)